Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

49.21
+0.34000.70%
Post-market: 49.210.00000.00%19:54 EDT
Volume:1.13M
Turnover:55.48M
Market Cap:8.26B
PE:126.75
High:49.58
Open:48.94
Low:48.87
Close:48.87
52wk High:55.67
52wk Low:25.17
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.88
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.56
PE(LYR):34.41

Loading ...

Alkermes price target raised to $61 from $54 at Needham

TIPRANKS
·
Jun 24

Alkermes is Maintained at Buy by Needham

Dow Jones
·
Jun 24

Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Alkermes (ALKS)

TIPRANKS
·
Jun 24

Alkermes Plc : Needham Raises Target Price to $61 from $54

THOMSON REUTERS
·
Jun 24

Alkermes Plc : Deutsche Bank Raises Target Price to $60 From $47

THOMSON REUTERS
·
Jun 22

Alkermes Plc : Needham Raises Target Price to $54 From $50

THOMSON REUTERS
·
Jun 18

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Alkermes (ALKS) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Jun 18

Alkermes data support alixorexton in narcolepsy type 2, says H.C. Wainwright

TIPRANKS
·
Jun 18

Alkermes Is Maintained at Buy by Needham

Dow Jones
·
Jun 18

Targeting the Brain's 'Wake Switch': Alkermes's Narcolepsy Drug Shows Promising Mid-Stage Data, Igniting Race in Orexin Pathway

Stock News
·
Jun 18

Alkermes' Phase 2 Trial of Alixorexton to Treat Narcolepsy Meets Dual Primary Endpoints

MT Newswires Live
·
Jun 18

Alkermes presents positive results from Phase 2 study of Alixorexton

TIPRANKS
·
Jun 18

Alkermes says phase 2 Vibrance-2 trial shows alixorexton improves wakefulness in narcolepsy type 2

Reuters
·
Jun 18

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at Sleep 2026

THOMSON REUTERS
·
Jun 18

Alkermes (ALKS) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 16

Alkermes' Sleep Disorder Drug Receives Orphan Drug Status in US and Europe

MT Newswires Live
·
Jun 15

Alkermes says alixorexton enters phase 3 Brilliance trials for narcolepsy type 1, type 2

Reuters
·
Jun 15

Alkermes says FDA grants orphan drug designation for alixorexton in idiopathic hypersomnia

Reuters
·
Jun 15

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

THOMSON REUTERS
·
Jun 15

Alkermes (ALKS) Stock Valuation After New Orphan Drug Designation For Alixorexton

Simply Wall St.
·
Jun 14